Showing 7131-7140 of 7494 results for "".
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- Cosmetic Treatments Jump 25 Percent in 2013: ASDS Surveyhttps://practicaldermatology.com/news/20140401-cosmetic_treatments_jump_25_percent_in_2013_asds_survey/2459283/The number of cosmetic procedures performed by members of the American Society for Dermatologic Surgery jumped to nearly 6.5 million in 2013 – an increase of 25 percent over the previous year, the ASDS Survey on Dermatologic Procedures shows.
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent pro
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen,
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas
- SeroVital®–hgh AKA the "Fountain of Youth" Pillhttps://practicaldermatology.com/news/20140320-serovitalhgh_aka_the_fountain_of_youth_pill/2459306/SeroVital®–hgh is a growth hormone that the maker says can reduce wrinkles, tighten skin, decrease body fat and increase energy. Gina Daines, spokesperson for SanMedica International™ said, "Human growth hormone is no longer solely the province of male athletes. Research is revealing tha
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new li
- Quinnova Pharmaceuticals Announces the Launch of Ecoza Foamhttps://practicaldermatology.com/news/20140319-quinnova_pharmaceuticals_announces_the_launch_of_ecoza_foam/2459310/Quinnova Pharmaceuticals LLC, an affiliate of Exeltis, launched its recently FDA-approved Ecoza (econazole nitrate) topical foam 1%. Ecoza Foma is indicated for the treatment of inter